Bolt Biotherapeutics, Inc.
BOLT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $1 | $0 |
| % Growth | 20.2% | 47.6% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $2 | $1 | -$0 |
| % Margin | 86.6% | 100% | 100% | – |
| R&D Expenses | $6 | $7 | $10 | $11 |
| G&A Expenses | $0 | $4 | $4 | $0 |
| SG&A Expenses | $3 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $11 | $13 | $15 |
| Operating Income | -$8 | -$9 | -$12 | -$16 |
| % Margin | -355.1% | -510.5% | -991.4% | – |
| Other Income/Exp. Net | $1 | $1 | $1 | -$0 |
| Pre-Tax Income | -$7 | -$9 | -$11 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$9 | -$11 | -$16 |
| % Margin | -329.4% | -474.6% | -903.4% | – |
| EPS | -3.722 | -4.46 | -0.29 | -0.42 |
| % Growth | 16.5% | -1,437.9% | 31% | – |
| EPS Diluted | -3.722 | -4.46 | -0.29 | -0.42 |
| Weighted Avg Shares Out | 2 | 2 | 38 | 38 |
| Weighted Avg Shares Out Dil | 2 | 2 | 38 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$9 | -$12 | -$16 |
| % Margin | -316% | -491.3% | -958.8% | – |